Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair and regeneration of human tendon, bone, nerve, and cartilage defects in Australia and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.53|
|52 Week High||AU$0.32|
|52 Week Low||AU$0.66|
|1 Month Change||7.07%|
|3 Month Change||0%|
|1 Year Change||39.47%|
|3 Year Change||125.53%|
|5 Year Change||11.58%|
|Change since IPO||47.22%|
Recent News & Updates
|OCC||AU Biotechs||AU Market|
Return vs Industry: OCC exceeded the Australian Biotechs industry which returned 1.5% over the past year.
Return vs Market: OCC exceeded the Australian Market which returned 20.2% over the past year.
Stable Share Price: OCC is less volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: OCC's weekly volatility (5%) has been stable over the past year.
About the Company
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair and regeneration of human tendon, bone, nerve, and cartilage defects in Australia and internationally. The company’s principal products include CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of tendons, peripheral nerves, bones, and articular cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation for the treatment of symptomatic defects of the articulating cartilage of the joints, primarily in the knee and ankle.
Orthocell Fundamentals Summary
|OCC fundamental statistics|
Is OCC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|OCC income statement (TTM)|
|Cost of Revenue||AU$625.65k|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.047|
|Net Profit Margin||-887.76%|
How did OCC perform over the long term?See historical performance and comparison
Is Orthocell undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate OCC's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate OCC's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: OCC is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.
PE vs Market: OCC is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate OCC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: OCC is overvalued based on its PB Ratio (6x) compared to the AU Biotechs industry average (4.9x).
How is Orthocell forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Orthocell has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Orthocell performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OCC is currently unprofitable.
Growing Profit Margin: OCC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: OCC is unprofitable, and losses have increased over the past 5 years at a rate of 18.5% per year.
Accelerating Growth: Unable to compare OCC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OCC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (46.5%).
Return on Equity
High ROE: OCC has a negative Return on Equity (-53.55%), as it is currently unprofitable.
How is Orthocell's financial position?
Financial Position Analysis
Short Term Liabilities: OCC's short term assets (A$17.1M) exceed its short term liabilities (A$1.9M).
Long Term Liabilities: OCC's short term assets (A$17.1M) exceed its long term liabilities (A$522.4K).
Debt to Equity History and Analysis
Debt Level: OCC is debt free.
Reducing Debt: OCC has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OCC has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: OCC has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 8.7% each year
What is Orthocell current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OCC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OCC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OCC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OCC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OCC's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Paul Anderson (55 yo)
Mr. Paul Frederick Anderson serves as Chief Executive Officer of Orthocell Limited. Mr. Anderson has been Managing Director and Executive Director of Orthocell Limited since March 21, 2006. Mr. Anderson ha...
CEO Compensation Analysis
Compensation vs Market: Paul's total compensation ($USD990.30K) is above average for companies of similar size in the Australian market ($USD302.72K).
Compensation vs Earnings: Paul's compensation has increased whilst the company is unprofitable.
Experienced Management: OCC's management team is seasoned and experienced (5.1 years average tenure).
Experienced Board: OCC's board of directors are considered experienced (8.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: OCC insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.6%.
Orthocell Limited's employee growth, exchange listings and data sources
- Name: Orthocell Limited
- Ticker: OCC
- Exchange: ASX
- Founded: 2006
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$101.508m
- Shares outstanding: 191.52m
- Website: https://www.orthocell.com.au
- Orthocell Limited
- Building 191
- Murdoch University
- Western Australia
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/18 15:30|
|End of Day Share Price||2021/10/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.